InterMune Halted Pending News

Shares of InterMune (NASDAQ: ITMN) were halted a short while ago pending news. More than likely it is related to their drug Esbriet(R) (pirfenidone), which is used to combat pulmonary fibrosis. Prior to the halting, the shares were down $5.41% to $45.44. Their were a few options trades today in the name, namely the May $25/35 put spread, which was purchased 2,000 times for $3.15.

InterMune reported a loss of $0.66 per share on April 29th, which was worse that Street expectations. Revenues were also off by 11.6% year over year.